BACKGROUND: Atrial fibrillation (AF) in heart failure (HF) is generally considered a
negative prognostic factor. Recent studies indicate that the incidence of AF might be …

BACKGROUND: Atrial fibrillation (AF) is frequent in patients with chronic heart failure (CHF).
Experimental and small patient studies have demonstrated that blocking the renin …

Objectives: We assessed the risk of adverse cardiovascular (CV) outcomes associated with
atrial fibrillation (AF) in the Candesartan in Heart failure-Assessment of Reduction in …

BACKGROUND: Atrial fibrillation is the most common cardiac arrhythmia, and no current
therapy is ideal for control of this condition. Experimental studies suggest that angiotensin II …

Background Atrial fibrillation is the most common cardiac arrhythmia, and no current therapy
is ideal for control of this condition. Experimental studies suggest that angiotensin II …

Aims Atrial fibrillation (AF) is an important morbidity–mortality risk factor, especially in
patients with heart failure (HF). Beta-blockers reduce morbidity and mortality in HF. The …

Background Atrial fibrillation (AF) is the most common arrhythmia and increases
cardiovascular risk in hypertensive patients. Therefore, in the Valsartan Antihypertensive …

Atrial fibrillation (AF) is the most common sustained arrhythmia. Congestive heart failure
(CHF), an increasingly frequent cardiovascular disorder affecting millions of people world …

Atrial fibrillation (AF) and chronic heart failure (CHF) are two major and even growing
cardiovascular conditions that often coexist. However, few data are available to guide …

Background Estimates of the prevalence of atrial fibrillation (AF) in heart failure (HF)
originate from patients enrolled in clinical trials. Aims To assess the prevalence and clinical …